Lexicon Pharmaceuticals, Inc. (LXRX)
USD 0.51
(2.75%)
USD 0.51
(2.75%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -171.75 Million USD | -70.45% |
| 2022 | -100.76 Million USD | -15.7% |
| 2021 | -87.09 Million USD | 51.29% |
| 2020 | -178.78 Million USD | -226.4% |
| 2019 | 141.44 Million USD | 236.95% |
| 2018 | -103.27 Million USD | 24.44% |
| 2017 | -136.68 Million USD | 0.35% |
| 2016 | -137.15 Million USD | -9442.98% |
| 2015 | 1.46 Million USD | 101.46% |
| 2014 | -100.36 Million USD | 1.96% |
| 2013 | -102.37 Million USD | 5.57% |
| 2012 | -108.41 Million USD | 4.98% |
| 2011 | -114.09 Million USD | -19.2% |
| 2010 | -95.71 Million USD | -6.41% |
| 2009 | -89.95 Million USD | 6.82% |
| 2008 | -96.53 Million USD | -28.79% |
| 2007 | -74.95 Million USD | -35.71% |
| 2006 | -55.23 Million USD | -52.91% |
| 2005 | -36.11 Million USD | 23.89% |
| 2004 | -47.45 Million USD | 24.19% |
| 2003 | -62.59 Million USD | 0.48% |
| 2002 | -62.89 Million USD | -44.12% |
| 2001 | -43.63 Million USD | -23.01% |
| 2000 | -35.47 Million USD | -177.16% |
| 1999 | -12.8 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -45.33 Million USD | 3.0% |
| 2024 Q2 | -55.35 Million USD | -22.11% |
| 2023 FY | -171.75 Million USD | -70.45% |
| 2023 Q3 | -49.63 Million USD | -12.19% |
| 2023 Q2 | -44.24 Million USD | -42.06% |
| 2023 Q1 | -31.14 Million USD | -2.85% |
| 2023 Q4 | -46.73 Million USD | 5.83% |
| 2022 Q3 | -23.09 Million USD | 3.8% |
| 2022 FY | -100.76 Million USD | -15.7% |
| 2022 Q1 | -23.38 Million USD | 7.7% |
| 2022 Q2 | -24 Million USD | -2.68% |
| 2022 Q4 | -30.27 Million USD | -31.1% |
| 2021 Q2 | -17.95 Million USD | 13.82% |
| 2021 FY | -87.09 Million USD | 51.29% |
| 2021 Q1 | -20.83 Million USD | -179.42% |
| 2021 Q3 | -22.96 Million USD | -27.86% |
| 2021 Q4 | -25.33 Million USD | -10.31% |
| 2020 FY | -178.78 Million USD | -226.4% |
| 2020 Q4 | -7.45 Million USD | -108.6% |
| 2020 Q1 | -62.43 Million USD | -32.24% |
| 2020 Q2 | -64.57 Million USD | -3.43% |
| 2020 Q3 | 86.67 Million USD | 234.22% |
| 2019 Q3 | 224.67 Million USD | 1311.52% |
| 2019 Q1 | -17.46 Million USD | -41.25% |
| 2019 Q2 | -18.54 Million USD | -6.16% |
| 2019 Q4 | -47.21 Million USD | -121.02% |
| 2019 FY | 141.44 Million USD | 236.95% |
| 2018 Q3 | -23.04 Million USD | 24.27% |
| 2018 Q1 | -37.96 Million USD | -23.33% |
| 2018 FY | -103.27 Million USD | 24.44% |
| 2018 Q2 | -30.42 Million USD | 19.85% |
| 2018 Q4 | -12.36 Million USD | 46.33% |
| 2017 FY | -136.68 Million USD | 0.35% |
| 2017 Q4 | -30.78 Million USD | -4.29% |
| 2017 Q3 | -29.51 Million USD | 12.91% |
| 2017 Q2 | -33.89 Million USD | 20.22% |
| 2017 Q1 | -42.48 Million USD | -35.6% |
| 2016 Q4 | -31.33 Million USD | 10.31% |
| 2016 Q3 | -34.93 Million USD | 5.64% |
| 2016 Q1 | -33.87 Million USD | -138.33% |
| 2016 FY | -137.15 Million USD | -9442.98% |
| 2016 Q2 | -37.02 Million USD | -9.3% |
| 2015 Q1 | -26.52 Million USD | -669.57% |
| 2015 Q4 | 88.36 Million USD | 362.37% |
| 2015 Q3 | -33.67 Million USD | -26.19% |
| 2015 Q2 | -26.68 Million USD | -0.61% |
| 2015 FY | 1.46 Million USD | 101.46% |
| 2014 FY | -100.36 Million USD | 1.96% |
| 2014 Q4 | -3.44 Million USD | 91.45% |
| 2014 Q3 | -40.33 Million USD | -54.48% |
| 2014 Q2 | -26.11 Million USD | 14.31% |
| 2014 Q1 | -30.47 Million USD | -79.5% |
| 2013 FY | -102.37 Million USD | 5.57% |
| 2013 Q2 | -28.62 Million USD | -12.01% |
| 2013 Q1 | -25.55 Million USD | -4.34% |
| 2013 Q3 | -31.21 Million USD | -9.06% |
| 2013 Q4 | -16.97 Million USD | 45.62% |
| 2012 Q4 | -24.49 Million USD | 15.72% |
| 2012 FY | -108.41 Million USD | 4.98% |
| 2012 Q2 | -25.48 Million USD | 13.28% |
| 2012 Q3 | -29.06 Million USD | -14.05% |
| 2012 Q1 | -29.38 Million USD | 11.87% |
| 2011 Q4 | -33.34 Million USD | -29.78% |
| 2011 Q1 | -29.13 Million USD | -29.93% |
| 2011 Q2 | -25.92 Million USD | 11.02% |
| 2011 Q3 | -25.69 Million USD | 0.91% |
| 2011 FY | -114.09 Million USD | -19.2% |
| 2010 Q3 | -24.25 Million USD | -0.74% |
| 2010 FY | -95.71 Million USD | -6.41% |
| 2010 Q2 | -24.07 Million USD | 3.57% |
| 2010 Q1 | -24.96 Million USD | -14.28% |
| 2010 Q4 | -22.42 Million USD | 7.54% |
| 2009 Q3 | -21.75 Million USD | 4.5% |
| 2009 FY | -89.95 Million USD | 6.82% |
| 2009 Q2 | -22.78 Million USD | 3.34% |
| 2009 Q1 | -23.57 Million USD | -12.83% |
| 2009 Q4 | -21.84 Million USD | -0.41% |
| 2008 Q1 | -24.43 Million USD | -32.33% |
| 2008 Q3 | -24.82 Million USD | 5.93% |
| 2008 Q2 | -26.38 Million USD | -7.97% |
| 2008 FY | -96.53 Million USD | -28.79% |
| 2008 Q4 | -20.88 Million USD | 15.84% |
| 2007 FY | -74.95 Million USD | -35.71% |
| 2007 Q2 | -17.95 Million USD | 6.0% |
| 2007 Q3 | -19.44 Million USD | -8.31% |
| 2007 Q4 | -18.46 Million USD | 5.01% |
| 2007 Q1 | -19.09 Million USD | -31.04% |
| 2006 Q4 | -14.57 Million USD | -14.69% |
| 2006 Q1 | -11.02 Million USD | -292.59% |
| 2006 FY | -55.23 Million USD | -52.91% |
| 2006 Q2 | -16.93 Million USD | -53.66% |
| 2006 Q3 | -12.7 Million USD | 24.96% |
| 2005 FY | -36.11 Million USD | 23.89% |
| 2005 Q1 | -13.26 Million USD | -809.95% |
| 2005 Q2 | -14.51 Million USD | -9.44% |
| 2005 Q3 | -14.05 Million USD | 3.2% |
| 2005 Q4 | 5.72 Million USD | 140.71% |
| 2004 Q1 | -15.6 Million USD | -26.43% |
| 2004 FY | -47.45 Million USD | 24.19% |
| 2004 Q3 | -13.94 Million USD | 15.17% |
| 2004 Q4 | -1.45 Million USD | 89.55% |
| 2004 Q2 | -16.44 Million USD | -5.39% |
| 2003 FY | -62.59 Million USD | 0.48% |
| 2003 Q3 | -14.86 Million USD | 16.72% |
| 2003 Q4 | -12.34 Million USD | 17.0% |
| 2003 Q1 | -17.53 Million USD | -20.21% |
| 2003 Q2 | -17.85 Million USD | -1.83% |
| 2002 FY | -62.89 Million USD | -44.12% |
| 2002 Q4 | -14.58 Million USD | 16.61% |
| 2002 Q3 | -17.49 Million USD | -11.84% |
| 2002 Q2 | -15.64 Million USD | -3.05% |
| 2002 Q1 | -15.17 Million USD | -20.21% |
| 2001 Q1 | -10.82 Million USD | 0.17% |
| 2001 FY | -43.63 Million USD | -23.01% |
| 2001 Q4 | -12.62 Million USD | -58.71% |
| 2001 Q3 | -7.95 Million USD | 34.99% |
| 2001 Q2 | -12.23 Million USD | -13.07% |
| 2000 Q4 | -10.84 Million USD | -121.66% |
| 2000 Q1 | -13.43 Million USD | 0.0% |
| 2000 FY | -35.47 Million USD | -177.16% |
| 2000 Q3 | -4.89 Million USD | 22.49% |
| 2000 Q2 | -6.3 Million USD | 53.04% |
| 1999 FY | -12.8 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Caribou Biosciences, Inc. | -116.05 Million USD | -47.985% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | -754.912% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | -401.211% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -238.804% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | -2.653% |
| C4 Therapeutics, Inc. | -139.03 Million USD | -23.534% |
| Agenus Inc. | -159.54 Million USD | -7.647% |
| Fortress Biotech, Inc. | -142.34 Million USD | -20.66% |
| GlycoMimetics, Inc. | -39.27 Million USD | -337.298% |
| Novavax, Inc. | -566.51 Million USD | 69.683% |
| Keros Therapeutics, Inc. | -169.94 Million USD | -1.064% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -14308.557% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | -77.593% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -5331.689% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | -271.303% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 39.134% |
| AlloVir, Inc. | -181.33 Million USD | 5.284% |
| Aptorum Group Limited | -10.52 Million USD | -1532.088% |
| Ardelyx, Inc. | -63.27 Million USD | -171.43% |
| Bicycle Therapeutics plc | -189.94 Million USD | 9.58% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 0.019% |
| Chimerix, Inc. | -93.06 Million USD | -84.548% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -281.012% |
| CRISPR Therapeutics AG | -222.53 Million USD | 22.822% |
| Clearside Biomedical, Inc. | -24.84 Million USD | -591.314% |
| Precision BioSciences, Inc. | -43.73 Million USD | -292.697% |
| Dyadic International, Inc. | -8.22 Million USD | -1986.943% |
| Elevation Oncology, Inc. | -45.44 Million USD | -277.929% |
| Fortress Biotech, Inc. | -142.34 Million USD | -20.66% |
| GT Biopharma, Inc. | -13.57 Million USD | -1165.1% |
| Alkermes plc | 414.12 Million USD | 141.473% |
| Immix Biopharma, Inc. | -16.14 Million USD | -964.053% |
| Innoviva, Inc. | 176.7 Million USD | 197.194% |
| IO Biotech, Inc. | -91.44 Million USD | -87.822% |
| Jaguar Health, Inc. | -34.29 Million USD | -400.86% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 1538.201% |
| ContextLogic Inc. | -328 Million USD | 47.637% |
| AbCellera Biologics Inc. | -237.2 Million USD | 27.595% |
| Lantern Pharma Inc. | -17.87 Million USD | -860.701% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -1920.351% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 16.22% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 54.862% |
| MEI Pharma, Inc. | 14.54 Million USD | 1281.062% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | -104.674% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -606.598% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | -30.623% |
| NextCure, Inc. | -67.63 Million USD | -153.929% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | -75.804% |
| ChromaDex Corporation | -5.59 Million USD | -2967.512% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | -27.763% |
| Incyte Corporation | 620.52 Million USD | 127.678% |
| Opthea Limited | -191.84 Million USD | 10.474% |
| MiMedx Group, Inc. | 37.11 Million USD | 562.738% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | -223.286% |
| Aadi Bioscience, Inc. | -71.93 Million USD | -138.764% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -6141.313% |
| Vaxcyte, Inc. | -468.04 Million USD | 63.304% |
| PDS Biotechnology Corporation | -43.04 Million USD | -298.999% |
| Pharming Group N.V. | -4.87 Million USD | -3419.796% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | -477.195% |
| Onconetix, Inc. | -36.03 Million USD | -376.625% |
| Acelyrin, Inc. | -422.06 Million USD | 59.307% |
| PureTech Health plc | -146.19 Million USD | -17.477% |
| Pyxis Oncology, Inc. | -82.19 Million USD | -108.952% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 27.1% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | -784.465% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -606.598% |
| ESSA Pharma Inc. | -32.13 Million USD | -434.479% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | -738.173% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -1525.959% |
| Seer, Inc. | -103.46 Million USD | -66.001% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 37.319% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | -353.537% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | -486.077% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -1331817.791% |
| Summit Therapeutics Inc. | -89.73 Million USD | -91.395% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | -363.388% |
| Senti Biosciences, Inc. | -92.72 Million USD | -85.221% |
| ImmuCell Corporation | -5.74 Million USD | -2887.955% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | -33.152% |
| Janux Therapeutics, Inc. | -72.97 Million USD | -135.342% |
| Precigen, Inc. | -88.92 Million USD | -93.145% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -202.595% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | -311.732% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | -49.643% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -290.252% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -4256.872% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 65.944% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | -161.181% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | -420.124% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -487.019% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -879.246% |
| Wave Life Sciences Ltd. | -67.99 Million USD | -152.588% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 9.848% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -2389.852% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 21.654% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 297.841% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | -233.456% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -1628.277% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 33.856% |
| Aptose Biosciences Inc. | -52.35 Million USD | -228.043% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | -1090.99% |
| Soligenix, Inc. | -7.69 Million USD | -2131.116% |
| Century Therapeutics, Inc. | -146.54 Million USD | -17.199% |
| Kura Oncology, Inc. | -165.8 Million USD | -3.586% |
| TScan Therapeutics, Inc. | -93.45 Million USD | -83.772% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -1964.551% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -6820.829% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -2548.828% |
| Autolus Therapeutics plc | -195.02 Million USD | 11.936% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -102.877% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | -133.16% |
| Eterna Therapeutics Inc. | -21.13 Million USD | -712.633% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 24.351% |
| GRI Bio, Inc. | -11.38 Million USD | -1408.299% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -3703.384% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | -30.914% |
| IGM Biosciences, Inc. | -263.46 Million USD | 34.81% |
| INmune Bio, Inc. | -29.74 Million USD | -477.486% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -55.268% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -351.08% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -974.824% |
| Entero Therapeutics, Inc. | -15.77 Million USD | -989.036% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | -181.106% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | -59.735% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 37.773% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 15.477% |
| Verastem, Inc. | -92.08 Million USD | -86.514% |
| Abeona Therapeutics Inc. | -47.13 Million USD | -264.379% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 6.731% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | -45.084% |
| Histogen Inc. | -10.64 Million USD | -1513.737% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | -1010.073% |
| Surrozen, Inc. | -45.78 Million USD | -275.164% |
| Organovo Holdings, Inc. | -15.08 Million USD | -1038.473% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -3274.107% |
| Ovid Therapeutics Inc. | -59.28 Million USD | -189.72% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -234.834% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | -579.391% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -2150.145% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | -0.273% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | -254.504% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | -119.615% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | -1028.392% |
| Apollomics, Inc. | -54.83 Million USD | -213.218% |
| Amarin Corporation plc | -67.58 Million USD | -154.113% |
| Mesoblast Limited | -58.79 Million USD | -192.122% |
| Turnstone Biologics Corp. | -59.03 Million USD | -190.944% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | -3.758% |
| Synaptogenix, Inc. | -8.31 Million USD | -1965.829% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | -1077.499% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | -87.314% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -3484.498% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -1844.802% |
| Exelixis, Inc. | 170.88 Million USD | 200.506% |
| Better Therapeutics, Inc. | -38.26 Million USD | -348.879% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | -10.761% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 66.787% |
| NLS Pharmaceutics AG | -11.8 Million USD | -1354.638% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -2035.688% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -472.634% |
| Gritstone bio, Inc. | -154.63 Million USD | -11.069% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -149.415% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | -903.034% |
| Avid Bioservices, Inc. | -18.67 Million USD | -819.531% |
| Insmed Incorporated | -709.62 Million USD | 75.797% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | -994.661% |
| MediWound Ltd. | -15.29 Million USD | -1023.283% |
| OmniAb, Inc. | -69.41 Million USD | -147.411% |
| Alector, Inc. | -151.74 Million USD | -13.187% |
| Seres Therapeutics, Inc. | -107.98 Million USD | -59.053% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -229.351% |
| Zai Lab Limited | -366.57 Million USD | 53.147% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 45.782% |
| Aura Biosciences, Inc. | -84.99 Million USD | -102.08% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 30.04% |
| Immunic, Inc. | -99.22 Million USD | -73.095% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | -19.972% |
| Veracyte, Inc. | -85.79 Million USD | -100.186% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 39.056% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -1108.656% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -2393.486% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | -813.923% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 129.685% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | -574.773% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 542.632% |
| TG Therapeutics, Inc. | 20.63 Million USD | 932.404% |
| Galecto, Inc. | -39.9 Million USD | -330.397% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -308.209% |
| Fortrea Holdings Inc. | 63.1 Million USD | 372.187% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | -22.29% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | -494.743% |
| XBiotech Inc. | -37.51 Million USD | -357.878% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -149.415% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | -155.885% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | -59.166% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -569.017% |
| Theravance Biopharma, Inc. | -53.29 Million USD | -222.281% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 69.826% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | -118.812% |
| Vaxxinity, Inc. | -58.28 Million USD | -194.673% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | -65.608% |
| Gain Therapeutics, Inc. | -22.25 Million USD | -671.801% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | -98.748% |
| NexImmune, Inc. | -29.19 Million USD | -488.336% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -2955.978% |
| Marker Therapeutics, Inc. | -14.58 Million USD | -1077.872% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 104.244% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | -574.614% |
| Scopus BioPharma Inc. | -11.71 Million USD | -1366.085% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | -35.17% |
| Ainos, Inc. | -13.2 Million USD | -1200.506% |
| Pluri Inc. | -22.15 Million USD | -675.115% |
| Prothena Corporation plc | -191.03 Million USD | 10.095% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | -24.422% |
| Celularity Inc. | -192.28 Million USD | 10.68% |
| Rallybio Corporation | -78.93 Million USD | -117.592% |
| Cue Biopharma, Inc. | -52.14 Million USD | -229.345% |
| MeiraGTx Holdings plc | -137.06 Million USD | -25.309% |
| Omeros Corporation | -164.53 Million USD | -4.388% |
| Humacyte, Inc. | -100.04 Million USD | -71.669% |
| Immunocore Holdings plc | -59.64 Million USD | -187.934% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | -825.427% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | -601.507% |
| Blueprint Medicines Corporation | -486.27 Million USD | 64.681% |
| CalciMedica, Inc. | -21.87 Million USD | -685.143% |
| Cabaletta Bio, Inc. | -74.66 Million USD | -130.043% |
| Scholar Rock Holding Corporation | -171.29 Million USD | -0.266% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 47.461% |
| Pulmatrix, Inc. | -14.74 Million USD | -1065.197% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | -380.487% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | -93.269% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 66.669% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | -154.252% |
| Cytokinetics, Incorporated | -496.2 Million USD | 65.387% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -398.998% |
| Nutriband Inc. | -4.87 Million USD | -3425.3% |
| Protara Therapeutics, Inc. | -43.61 Million USD | -293.805% |
| Vor Biopharma Inc. | -126.03 Million USD | -36.271% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 104.049% |
| Evogene Ltd. | -26.39 Million USD | -550.79% |
| ProKidney Corp. | -151.52 Million USD | -13.35% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -166.135% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -2132.769% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 71.722% |
| CorMedix Inc. | -48.95 Million USD | -250.812% |
| BioLineRx Ltd. | -49.69 Million USD | -245.615% |
| Tango Therapeutics, Inc. | -114.17 Million USD | -50.43% |
| Galectin Therapeutics Inc. | -38.07 Million USD | -351.119% |
| Atai Life Sciences N.V. | -125.47 Million USD | -36.884% |
| Renovaro Biosciences Inc. | -81.63 Million USD | -110.377% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | -110.972% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 31.021% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -458.718% |
| MediciNova, Inc. | -9.9 Million USD | -1634.802% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | -35.907% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -2271.432% |
| GeoVax Labs, Inc. | -26.74 Million USD | -542.226% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 25.914% |
| Biomea Fusion, Inc. | -126.13 Million USD | -36.164% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 50.845% |
| Mereo BioPharma Group plc | -28.41 Million USD | -504.413% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 10.12% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 25.311% |
| Absci Corporation | -115.51 Million USD | -48.682% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -522.576% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | -52.17% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 29.076% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | -581.656% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 17.426% |
| Allakos Inc. | -196.05 Million USD | 12.397% |
| Imunon, Inc. | -21.03 Million USD | -716.674% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | -55.2% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 260.092% |
| BioAtla, Inc. | -129.68 Million USD | -32.434% |
| NLS Pharmaceutics AG | -11.8 Million USD | -1354.638% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -984.075% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 47.595% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | -311.298% |
| XOMA Corporation | -41.84 Million USD | -310.414% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | -63.203% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -41.364% |
| aTyr Pharma, Inc. | -54.91 Million USD | -212.733% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | -96.45% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 0.648% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 32.501% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | -700.102% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -1991.259% |
| Akari Therapeutics, Plc | -16.8 Million USD | -921.956% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -1942107.592% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 150.878% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -2528.549% |
| UroGen Pharma Ltd. | -65.53 Million USD | -162.07% |
| Sutro Biopharma, Inc. | -89.27 Million USD | -92.377% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -2264.721% |
| Orgenesis Inc. | -53.63 Million USD | -220.214% |
| Entera Bio Ltd. | -8.89 Million USD | -1831.729% |
| GH Research PLC | -41.22 Million USD | -316.646% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | -568.08% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | -106.796% |
| Xencor, Inc. | -138.63 Million USD | -23.883% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -3231.986% |
| Replimune Group, Inc. | -234.77 Million USD | 26.844% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | -699.167% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | -1131.006% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -2528.549% |
| Portage Biotech Inc. | -18.25 Million USD | -840.941% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -2271.432% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | -63.632% |
| OncoCyte Corporation | -25.13 Million USD | -583.283% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -1419.258% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -1399.076% |
| Purple Biotech Ltd. | 22.27 Million USD | 871.182% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -2186.342% |
| scPharmaceuticals Inc. | -55.39 Million USD | -210.04% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | -808.841% |
| HilleVax, Inc. | -133.34 Million USD | -28.801% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -1325.429% |
| Tharimmune, Inc. | -9.45 Million USD | -1716.457% |
| Genprex, Inc. | -31.07 Million USD | -452.685% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 8.738% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | -447.375% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -22350.98% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -3053.159% |
| OKYO Pharma Limited | -15.74 Thousand USD | -1090394.885% |
| Savara Inc. | -60 Million USD | -186.217% |
| Curis, Inc. | -48.33 Million USD | -255.355% |
| Daré Bioscience, Inc. | -30.83 Million USD | -456.909% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -3191.945% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -2260.176% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | -530.275% |
| BeiGene, Ltd. | -1.2 Billion USD | 85.779% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -761.364% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 64.746% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | -83.392% |
| Erasca, Inc. | -141.52 Million USD | -21.357% |
| bluebird bio, Inc. | -244.26 Million USD | 29.686% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -3693.925% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 188.33% |
| DBV Technologies S.A. | -76.43 Million USD | -124.71% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -3693.925% |
| Moderna, Inc. | -4.23 Billion USD | 95.948% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -303.084% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -2600.472% |
| Molecular Templates, Inc. | -10.46 Million USD | -1541.028% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | -155.44% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 54.412% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | -19.844% |
| Spruce Biosciences, Inc. | -51.99 Million USD | -230.333% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | -11.135% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 17.479% |
| MacroGenics, Inc. | -168.24 Million USD | -2.084% |
| RenovoRx, Inc. | -11.39 Million USD | -1407.108% |
| Adicet Bio, Inc. | -152.03 Million USD | -12.965% |
| Prime Medicine, Inc. | -191.29 Million USD | 10.216% |
| Aditxt, Inc. | -26.06 Million USD | -558.995% |
| Adagene Inc. | -23.71 Million USD | -624.077% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -2249.49% |
| Quantum-Si incorporated | -111.17 Million USD | -54.492% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | -442.688% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -1078.164% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 240.763% |
| SciSparc Ltd. | -5.77 Million USD | -2875.056% |
| Vericel Corporation | -6.46 Million USD | -2557.024% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -1884.021% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | -642.877% |
| Generation Bio Co. | -138.56 Million USD | -23.951% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -106.853% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | -98.647% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 28.764% |
| Invivyd, Inc. | -207.78 Million USD | 17.342% |
| Relay Therapeutics, Inc. | -373 Million USD | 53.954% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -1731.316% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 899.544% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -1569.583% |
| 2seventy bio, Inc. | -216.7 Million USD | 20.744% |
| ADMA Biologics, Inc. | 21.63 Million USD | 893.963% |
| Clene Inc. | -40.54 Million USD | -323.656% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | -613.311% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | -213.435% |
| GeoVax Labs, Inc. | -26.74 Million USD | -542.226% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 50.937% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | -367.576% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 1168.296% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | -65.619% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -405.117% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | -0.864% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 74.902% |
| Evaxion Biotech A/S | -22.19 Million USD | -673.753% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | -108.48% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 23.025% |
| Trevena, Inc. | -35.28 Million USD | -386.709% |
| Surrozen, Inc. | -45.78 Million USD | -275.164% |
| Tyra Biosciences, Inc. | -79.94 Million USD | -114.835% |
| Cingulate Inc. | -22.75 Million USD | -654.64% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 2392.445% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -284.512% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -1985.878% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | -67.466% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | -134.059% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | -176.686% |
| Clearmind Medicine Inc. | -8.74 Million USD | -1864.799% |
| Kronos Bio, Inc. | -121.83 Million USD | -40.975% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | -125.406% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -5755.809% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -70.341% |
| Statera Biopharma, Inc. | -98.34 Million USD | -74.642% |
| ImmunityBio, Inc. | -362.25 Million USD | 52.588% |
| Korro Bio, Inc. | -84.53 Million USD | -103.173% |
| Kineta, Inc. | -15.72 Million USD | -992.349% |
| BioVie Inc. | -32.17 Million USD | -433.723% |
| Codexis, Inc. | -68.06 Million USD | -152.318% |
| Celularity Inc. | -192.28 Million USD | 10.68% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 22.846% |
| Celcuity Inc. | -66.23 Million USD | -159.322% |
| Virax Biolabs Group Limited | -6.49 Million USD | -2543.742% |
| Cibus, Inc. | -318.88 Million USD | 46.14% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | -299.419% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -407.475% |
| IN8bio, Inc. | -30.33 Million USD | -466.14% |
| Kodiak Sciences Inc. | -277.32 Million USD | 38.068% |
| Annexon, Inc. | -143.72 Million USD | -19.501% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | -38.742% |
| Assembly Biosciences, Inc. | -64.64 Million USD | -165.678% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | -632.597% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 51.446% |
| Eyenovia, Inc. | -25.4 Million USD | -576.01% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 626.195% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -2987.918% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | -117.04% |
| Arcellx, Inc. | -89.88 Million USD | -91.088% |
| Cardiff Oncology, Inc. | -45.41 Million USD | -278.204% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | -25.176% |
| Regulus Therapeutics Inc. | -31.1 Million USD | -452.091% |
| Moolec Science SA | -6.65 Million USD | -2481.23% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | -180.922% |
| Geron Corporation | -193.94 Million USD | 11.444% |
| LAVA Therapeutics N.V. | -43.25 Million USD | -297.082% |
| Royalty Pharma plc | 1.49 Billion USD | 111.51% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | -4.622% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -1741.257% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | -684.438% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | -0.464% |
| Humacyte, Inc. | -100.04 Million USD | -71.669% |
| Structure Therapeutics Inc. | -102.77 Million USD | -67.113% |
| 89bio, Inc. | -151.2 Million USD | -13.588% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | -114.334% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | -1081.224% |
| Genelux Corporation | -24.16 Million USD | -610.739% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | -406.294% |
| Notable Labs, Ltd. | -14.65 Million USD | -1071.795% |
| Liquidia Corporation | -73.38 Million USD | -134.043% |
| Mustang Bio, Inc. | -50.72 Million USD | -238.584% |
| Immunovant, Inc. | -282.7 Million USD | 39.248% |
| Quantum-Si incorporated | -111.17 Million USD | -54.492% |
| Arbutus Biopharma Corporation | -78.1 Million USD | -119.902% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | -707.589% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -68.363% |
| Acasti Pharma Inc. | -11.31 Million USD | -1418.299% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | -649.309% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -974.824% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 19.763% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -4581.02% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -981.141% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | -489.052% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | -315.015% |
| PepGen Inc. | -84.76 Million USD | -102.617% |
| Moleculin Biotech, Inc. | -29.63 Million USD | -479.629% |
| United Therapeutics Corporation | 1.18 Billion USD | 114.495% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -650.098% |
| Solid Biosciences Inc. | -104.31 Million USD | -64.646% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | -423.498% |
| Immuneering Corporation | -58.41 Million USD | -194.028% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -3274.107% |
| Silo Pharma, Inc. | -3.85 Million USD | -4354.569% |
| Belite Bio, Inc | -31.66 Million USD | -442.346% |
| XOMA Corporation | -41.84 Million USD | -310.414% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | -154.369% |
| Bionomics Limited | -17.89 Billion USD | 99.04% |
| Apogee Therapeutics, Inc. | -93 Million USD | -84.671% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 581.362% |
| uniQure N.V. | -282.87 Million USD | 39.283% |
| Cassava Sciences, Inc. | -105.95 Million USD | -62.094% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -2249.49% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | -32.621% |
| Forte Biosciences, Inc. | -32.48 Million USD | -428.689% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -1967.097% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | -484.283% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -2987.918% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -1108.656% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -1832.163% |
| Altimmune, Inc. | -95.92 Million USD | -79.039% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -133.693% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 581.362% |
| Compugen Ltd. | -12.99 Million USD | -1221.967% |
| Peak Bio, Inc. | -1356.23 USD | -12663681.217% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | -246.242% |
| Benitec Biopharma Inc. | -22.49 Million USD | -663.673% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 29.118% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | -477.389% |
| Zura Bio Limited | -62.63 Million USD | -174.195% |
| PolyPid Ltd. | -22.86 Million USD | -651.082% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | -955.235% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | -477.389% |
| Instil Bio, Inc. | -159.16 Million USD | -7.904% |
| argenx SE | -425.04 Million USD | 59.593% |
| Immunome, Inc. | -109.53 Million USD | -56.806% |
| Compass Therapeutics, Inc. | -50.36 Million USD | -241.024% |
| Verona Pharma plc | -67.83 Million USD | -153.203% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | -559.056% |
| Shattuck Labs, Inc. | -91.95 Million USD | -86.772% |
| CervoMed Inc. | -7.81 Million USD | -2098.289% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | -134.92% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -1189.318% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -256.52% |
| Moolec Science SA | -6.65 Million USD | -2481.23% |
| Enveric Biosciences, Inc. | -16.44 Million USD | -944.172% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | -27.009% |
| AnaptysBio, Inc. | -164.41 Million USD | -4.464% |
| Design Therapeutics, Inc. | -78.19 Million USD | -119.657% |
| Leap Therapeutics, Inc. | -87.04 Million USD | -97.321% |
| NeurAxis, Inc. | -6.66 Million USD | -2477.089% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | -324.085% |
| Lumos Pharma, Inc. | -36.61 Million USD | -369.083% |
| Achilles Therapeutics plc | -75.25 Million USD | -128.224% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | -559.056% |
| 180 Life Sciences Corp. | -13.47 Million USD | -1174.346% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 3430.87% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -5755.809% |
| Nutriband Inc. | -4.87 Million USD | -3425.3% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | -55.037% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | -209.744% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | -237.851% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | -159.838% |
| MoonLake Immunotherapeutics | -54.12 Million USD | -217.332% |
| Palisade Bio, Inc. | -13.07 Million USD | -1214.078% |
| Tourmaline Bio, Inc. | -45.4 Million USD | -278.229% |
| Beam Therapeutics Inc. | -176.48 Million USD | 2.683% |
| Neurogene Inc. | -55.58 Million USD | -208.997% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | -57.347% |
| AEON Biopharma, Inc. | -48.42 Million USD | -254.643% |
| Sesen Bio, Inc. | -25.9 Million USD | -562.897% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | -105.617% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -1264.514% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 62.708% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | -137.096% |
| Athira Pharma, Inc. | -125.46 Million USD | -36.89% |
| Vaccinex, Inc. | -22.88 Million USD | -650.492% |
| HCW Biologics Inc. | -25.71 Million USD | -567.842% |
| XOMA Corporation | -41.84 Million USD | -310.414% |
| Nektar Therapeutics | -137.42 Million USD | -24.977% |
| Arvinas, Inc. | -401.5 Million USD | 57.223% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -1942107.592% |
| Merus N.V. | -156.54 Million USD | -9.711% |
| Omega Therapeutics, Inc. | -100.26 Million USD | -71.303% |
| Quince Therapeutics, Inc. | -34.62 Million USD | -396.101% |
| Rezolute, Inc. | -70.42 Million USD | -143.883% |
| Clene Inc. | -40.54 Million USD | -323.656% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | -948.632% |
| BeyondSpring Inc. | -23.11 Million USD | -643.056% |
| Synlogic, Inc. | -55.16 Million USD | -211.361% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | -857.945% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -1486.752% |
| Peak Bio, Inc. | -1356.23 USD | -12663681.217% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | -324.043% |
| Krystal Biotech, Inc. | -109.72 Million USD | -56.525% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | -32.585% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 49.929% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -3518.873% |
| MannKind Corporation | 8.67 Million USD | 2079.143% |
| Ikena Oncology, Inc. | -75.41 Million USD | -127.734% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -1680.346% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | -155.466% |
| Gossamer Bio, Inc. | -183.75 Million USD | 6.535% |
| CohBar, Inc. | -12.38 Million USD | -1286.389% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | -238.597% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -522.576% |
| Legend Biotech Corporation | -439.48 Million USD | 60.92% |
| Mural Oncology plc | -194.63 Million USD | 11.759% |
| Biora Therapeutics, Inc. | -67.14 Million USD | -155.797% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -963.779% |
| Disc Medicine, Inc. | -91.12 Million USD | -88.477% |
| Champions Oncology, Inc. | -7.35 Million USD | -2234.829% |
| REGENXBIO Inc. | -268.12 Million USD | 35.945% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -1502.417% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -208.039% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | -340.829% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | -50.188% |
| Vaxart, Inc. | -83.34 Million USD | -106.066% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -1915.843% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | -301.341% |
| Cellectis S.A. | -106.62 Million USD | -61.077% |
| Longeveron Inc. | -21.02 Million USD | -716.729% |
| Repare Therapeutics Inc. | -116.22 Million USD | -47.775% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 35.872% |
| Inozyme Pharma, Inc. | -75.64 Million USD | -127.047% |
| Revolution Medicines, Inc. | -487.18 Million USD | 64.746% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -2481.93% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | -290.749% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -130.259% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | -146.643% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -1459.804% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 103.987% |
| Denali Therapeutics Inc. | -196.69 Million USD | 12.684% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -1884.021% |
| Veru Inc. | -93.78 Million USD | -83.137% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | -636.208% |
| Cingulate Inc. | -22.75 Million USD | -654.64% |
| Passage Bio, Inc. | -108.38 Million USD | -58.457% |
| Context Therapeutics Inc. | -25.07 Million USD | -585.01% |
| Exicure, Inc. | -14.99 Million USD | -1045.305% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 16.652% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | -323.05% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -1667.532% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 6.838% |
| Nuvalent, Inc. | -149.49 Million USD | -14.889% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -1990.304% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | -93.563% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | -726.755% |
| OmniAb, Inc. | -69.41 Million USD | -147.411% |
| Anew Medical, Inc. | -1.3 Million USD | -13103.007% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -1244.844% |
| Lipocine Inc. | -17.93 Million USD | -857.841% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | -150.682% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | -125.536% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -351.08% |
| G1 Therapeutics, Inc. | -39.52 Million USD | -334.513% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | -667.289% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 70.38% |
| Ocugen, Inc. | -65.53 Million USD | -162.09% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | -82.974% |
| Q32 Bio Inc. | -92.1 Million USD | -86.478% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | -701.11% |
| Alumis Inc. Common Stock | -158.17 Million USD | -8.583% |
| Equillium, Inc. | -14.52 Million USD | -1082.688% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | -175.214% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -2073.129% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -810.411% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -265.807% |
| Evelo Biosciences, Inc. | -108.46 Million USD | -58.345% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -1334.835% |
| Dominari Holdings Inc. | -21.79 Million USD | -687.989% |
| Edesa Biotech, Inc. | -9.22 Million USD | -1762.241% |
| vTv Therapeutics Inc. | -25.5 Million USD | -573.477% |
| Bio-Techne Corporation | 206.68 Million USD | 183.097% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 56.129% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 189.439% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | -29.841% |
| Candel Therapeutics, Inc. | -38.39 Million USD | -347.37% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | -13.666% |
| Nkarta, Inc. | -131.65 Million USD | -30.46% |
| BioCardia, Inc. | -11.64 Million USD | -1375.009% |
| Iterum Therapeutics plc | -47.46 Million USD | -261.823% |